

CLAIMS

1. A process for producing a block copolymer-drug composite, comprising the steps of dissolving an AB type block copolymer composed of hydrophilic polymer structure moiety and hydrophobic polyamino acid structure moiety together with a drug in water or a mixed solvent of water and a low-boiling-point organic solvent miscible with water, and concentrating the resultant solution.

2. The process for producing a block copolymer-drug composite according to Claim 1, wherein neither dialysis nor ultrafiltration process is included in the production process.

3. The process for producing a block copolymer-drug composite according to Claim 1 or 2, wherein the hydrophilic polymer structure moiety in the AB type block copolymer is a polyethylene oxide derivative, and the hydrophobic polyamino acid structure moiety in the AB type block copolymer is polyaspartic acid containing aspartic acid having a side chain carboxyl group bonded by an anthracycline-based anticancer agent.

4. The process for producing a block copolymer-drug composite according to Claim 1 or 2, wherein the hydrophilic polymer structure moiety in the AB type block copolymer is a polyethylene oxide derivative, and the hydrophobic polyamino acid structure moiety in the AB type block copolymer is polyglutamic acid containing glutamic acid having a side chain carboxyl group bonded by an anthracycline-based anticancer

agent.

5. The process for producing a block copolymer-drug composite according to Claim 3 or 4, wherein the anthracycline-based anticancer agent bonded to a side chain carboxyl group on the hydrophobic polyamino acid structure moiety is doxorubicin.

6. The process for producing a block copolymer-drug composite according to any one of Claims 1 to 5, wherein the drug is an anthracycline-based anticancer agent.

7. The process for producing a block copolymer-drug composite according to Claim 6, wherein the anthracycline-based anticancer agent is doxorubicin or a salt thereof.

8. A process for producing a lyophilization preparation containing a block copolymer-drug composite, comprising the steps of dissolving an AB type block copolymer composed of hydrophilic polymer structure moiety and hydrophobic polyamino acid structure moiety together with a drug in water or a mixed solvent of water and a low-boiling-point organic solvent miscible with water, concentrating the resultant solution, and further lyophilizing this.